Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
European Journal of Drug Metabolism and Pharmacokinetics
|
December 24, 2024
Mass Balance Recovery, Absorption, Metabolism, and Excretion of Elinzanetant in Healthy Human Volunteers and in vitro Biotransformation
Simone I Schulz, Marcus-Hillert Schultze-Mosgau, Anna Engelen, et al.
Clinical Pharmacology and Therapeutics
|
July 28, 2023
Quantitative Systems Toxicology Identifies Independent Mechanisms for Hepatotoxicity and Bilirubin Elevations Due to AKR1C3 Inhibitor BAY1128688
Christina Battista, Lisl K M Shoda, Paul B Watkins, et al.
Chemmedchem
|
November 9, 2018
Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies
Carsten Möller, Wilhelm Bone, Arwed Cleve, et al.
Clinical Pharmacology and Therapeutics
|
April 11, 2020
The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam
Herbert Wiesinger, Stefan Klein, Antje Rottmann, et al.
British Journal of Clinical Pharmacology
|
September 2, 2018
CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans
Niladri Chattopadhyay, Tobias Kanacher, Manuela Casjens, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
December 3, 2023
Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers
Stefanie Reif, Marcus-Hillert Schultze-Mosgau, Anna Engelen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 3, 2006
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients
Lorenz M Jost, Hans-Peter Gschwind, Tarja Jalava, et al.
European Journal of Endocrinology
|
June 12, 2023
Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study
Isabella Gashaw, Stefanie Reif, Herbert Wiesinger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 9, 2013
Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men
Anne Roivainen, Esa Kähkönen, Pauliina Luoto, et al.
Drugs in R&D
|
July 9, 2023
Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis
Jan Hilpert, Esther Groettrup-Wolfers, Hristiyan Kosturski, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
European Journal of Drug Metabolism and Pharmacokinetics
|
December 24, 2024
Mass Balance Recovery, Absorption, Metabolism, and Excretion of Elinzanetant in Healthy Human Volunteers and in vitro Biotransformation
Simone I Schulz, Marcus-Hillert Schultze-Mosgau, Anna Engelen, et al.
Clinical Pharmacology and Therapeutics
|
July 28, 2023
Quantitative Systems Toxicology Identifies Independent Mechanisms for Hepatotoxicity and Bilirubin Elevations Due to AKR1C3 Inhibitor BAY1128688
Christina Battista, Lisl K M Shoda, Paul B Watkins, et al.
Chemmedchem
|
November 9, 2018
Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies
Carsten Möller, Wilhelm Bone, Arwed Cleve, et al.
Clinical Pharmacology and Therapeutics
|
April 11, 2020
The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam
Herbert Wiesinger, Stefan Klein, Antje Rottmann, et al.
British Journal of Clinical Pharmacology
|
September 2, 2018
CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans
Niladri Chattopadhyay, Tobias Kanacher, Manuela Casjens, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
December 3, 2023
Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers
Stefanie Reif, Marcus-Hillert Schultze-Mosgau, Anna Engelen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 3, 2006
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients
Lorenz M Jost, Hans-Peter Gschwind, Tarja Jalava, et al.
European Journal of Endocrinology
|
June 12, 2023
Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study
Isabella Gashaw, Stefanie Reif, Herbert Wiesinger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 9, 2013
Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men
Anne Roivainen, Esa Kähkönen, Pauliina Luoto, et al.
Drugs in R&D
|
July 9, 2023
Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis
Jan Hilpert, Esther Groettrup-Wolfers, Hristiyan Kosturski, et al.
Page
of 3